Pfizer Inc. has been criticized by Starboard Value LP's CEO Jeffrey Smith for causing a loss of $20 billion in value. Smith attributes this decline to Pfizer's failure to deliver on its promising pipeline of new drugs.

Smith expressed the need for increased accountability within the company during his speech at the 13D Monitor Active-Passive Investor Summit in New York. He pointed out the significant drop in Pfizer's share price since the start of the Covid pandemic, describing the situation as "crazy."

These remarks from Smith reflect the growing concerns among investors about Pfizer's future prospects and the effectiveness of its strategic direction.